JP Morgan, one of the largest banks in the United States and one of Wall Street’s leading operators, established a target price of $ 60 for Hapvida shares, more than 60% above the current price. The institution recommended the purchase of the papers.
The quotation of Hapvida’s action was R $ 36.65 at 17h today (+1.05%).
According to the bank’s report, the Brazilian carrier continues to show strong profitability, and is well positioned to capture margin gains as its sinister cash rate (indicator used in the supplementary health sector to measure the relationship between care costs actually paid in a period and the revenue received in the same period).
Hapvida is the largest healthcare operator in Latin America, the result of the merger with the intermediate Notredame in 2022.
